No Increased CVD Risk With IL-6 Blocker in RA (CME/CE)
(MedPage Today) -- Concerns had been raised because of elevated lipids with tocilizumab use (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 5, 2018 Category: Cardiology Source Type: news

Accelerated Subcutaneous Nodulosis in Tocilizumab-Treated RA Accelerated Subcutaneous Nodulosis in Tocilizumab-Treated RA
This report details new and worsening subcutaneous nodulosis in a case series of patients with rheumatoid arthritis treated with the monoclonal antibody tocilizumab.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 15, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

New jab to help patients at risk of going blind from common condition
Tocilizumab, a drug that targets a chemical responsible for inflammation, could help countless people with giant cell arteritis (GCA). (Source: the Mail online | Health)
Source: the Mail online | Health - July 9, 2018 Category: Consumer Health News Source Type: news

Roche ’s RoActemra gains positive CHMP opinion for CAR T-cell-induced cytokine release syndrome
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of RoActemra ® (tocilizumab) for the treatment of cytokine release syndrome (CRS), in adults and pediatric patients aged two years and older. (Source: Roche Investor Update)
Source: Roche Investor Update - June 29, 2018 Category: Pharmaceuticals Source Type: news

Meds Improve Cardiovascular Risk in RA
(MedPage Today) -- Benefits seen for hydroxychloroquine, methotrexate, and tocilizumab (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 15, 2018 Category: Cardiology Source Type: news

No difference in malignancy rates seen between tocilizumab and TNFi in patients with RA
(European League Against Rheumatism) The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2018) examined rates of malignancy in patients with rheumatoid arthritis (RA), excluding non-melanoma skin cancer (NMSC), and found no difference between those newly treated with tocilizumab (TCZ) versus TNF inhibitors (TNFi). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 15, 2018 Category: Cancer & Oncology Source Type: news

Safe Stopping of Tocilizumab in RA: MTX Helps Safe Stopping of Tocilizumab in RA: MTX Helps
Patients with rheumatoid arthritis who achieve 6 months of remission or low disease activity by taking methotrexate plus tocilizumab can usually stop tocilizumab; restarting is effective if flares occur.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 13, 2018 Category: Consumer Health News Tags: Rheumatology News Source Type: news

FDA approves subcutaneous formulation of Actemra for use in active polyarticular juvenile idiopathic arthritis (pJIA), a rare form of juvenile arthritis
Roche announced today that the US Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra ® (tocilizumab) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older. (Source: Roche Investor Update)
Source: Roche Investor Update - May 15, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Subcutaneous Formulation of Actemra for use in Active Polyarticular Juvenile Idiopathic Arthritis
South San Francisco, CA -- May 14, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra ®... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 14, 2018 Category: Drugs & Pharmacology Source Type: news

Tocilizumab Beats Anti-TNFs for Treatment Retention
(MedPage Today) -- Longer time on treatment, regardless of additional DMARDs (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - May 8, 2018 Category: Rheumatology Source Type: news

High CV Risk Not Seen for Tocilizumab (CME/CE)
(MedPage Today) -- Despite elevated lipids seen with the IL-6 blocker (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 4, 2018 Category: Cardiology Source Type: news

Biologics Differ in Safety Risks (CME/CE)
(MedPage Today) -- Infection risks higher for tocilizumab (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 2, 2018 Category: Primary Care Source Type: news

Cipla's U-turn: Happily ever after?
In a foes-turn-friends move announced on February 27, the Mumbai-based drug maker announced that it will partner Swiss biotech company Roche to promote Actemra and Syndyma. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 1, 2018 Category: Pharmaceuticals Source Type: news

Cipla ties up with Roche to sell 2 cancer drugs in India
The pharma major will distribute Tocilizumab and Syndyma -- the second brand of Roche's cancer therapy bevacizumab -- in India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 27, 2018 Category: Pharmaceuticals Source Type: news